Citigroup Inc. Cuts AMAG Pharmaceuticals, Inc. (AMAG) Price Target to $24.00

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) had its price target lowered by Citigroup Inc. to $24.00 in a research report report published on Friday, The Fly reports. The brokerage currently has a hold rating on the specialty pharmaceutical company’s stock.

A number of other research firms have also recently issued reports on AMAG. Jefferies Group LLC set a $40.00 price target on AMAG Pharmaceuticals and gave the company a buy rating in a report on Saturday, March 18th. Cantor Fitzgerald reaffirmed a hold rating and issued a $23.00 price target on shares of AMAG Pharmaceuticals in a report on Tuesday, May 2nd. Barclays PLC reaffirmed a hold rating and issued a $25.00 price target on shares of AMAG Pharmaceuticals in a report on Friday, May 5th. TheStreet cut AMAG Pharmaceuticals from a c rating to a d+ rating in a report on Friday, May 5th. Finally, ValuEngine cut AMAG Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, May 11th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of Hold and an average target price of $28.09.

Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 19.67 on Friday. AMAG Pharmaceuticals has a 12-month low of $16.00 and a 12-month high of $36.83. The firm’s market cap is $689.51 million. The company has a 50 day moving average of $18.02 and a 200-day moving average of $23.21.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings data on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.09 by $1.15. The company had revenue of $139.47 million for the quarter, compared to the consensus estimate of $150.32 million. AMAG Pharmaceuticals had a negative net margin of 5.61% and a positive return on equity of 1.69%. The firm’s revenue was up 27.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.22) earnings per share. Equities research analysts forecast that AMAG Pharmaceuticals will post $5.12 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Citigroup Inc. Cuts AMAG Pharmaceuticals, Inc. (AMAG) Price Target to $24.00” was originally published by BBNS and is the sole property of of BBNS. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://baseballnewssource.com/markets/citigroup-inc-cuts-amag-pharmaceuticals-inc-amag-price-target-to-24-00/1180295.html.

In other AMAG Pharmaceuticals news, SVP Julie Krop sold 1,891 shares of the business’s stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $24.45, for a total transaction of $46,234.95. Following the completion of the sale, the senior vice president now directly owns 36,777 shares of the company’s stock, valued at approximately $899,197.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.80% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Cornerstone Financial Partners LLC raised its position in AMAG Pharmaceuticals by 306.3% in the first quarter. Cornerstone Financial Partners LLC now owns 49,492 shares of the specialty pharmaceutical company’s stock valued at $1,116,000 after buying an additional 37,312 shares during the last quarter. Bank of Montreal Can raised its position in AMAG Pharmaceuticals by 4,071.4% in the first quarter. Bank of Montreal Can now owns 66,492 shares of the specialty pharmaceutical company’s stock valued at $1,500,000 after buying an additional 64,898 shares during the last quarter. Creative Planning raised its position in AMAG Pharmaceuticals by 768.4% in the first quarter. Creative Planning now owns 13,895 shares of the specialty pharmaceutical company’s stock valued at $313,000 after buying an additional 12,295 shares during the last quarter. Teachers Advisors LLC raised its position in AMAG Pharmaceuticals by 9.5% in the fourth quarter. Teachers Advisors LLC now owns 59,891 shares of the specialty pharmaceutical company’s stock valued at $2,084,000 after buying an additional 5,216 shares during the last quarter. Finally, Norges Bank bought a new position in AMAG Pharmaceuticals during the fourth quarter valued at about $19,914,000.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

The Fly

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana


Leave a Reply

 
© 2006-2017 BBNS.